<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025636</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068981</org_study_id>
    <secondary_id>GHSG-HD-R2</secondary_id>
    <secondary_id>EBMT-GHSG-HD-R2</secondary_id>
    <secondary_id>EORTC-20011</secondary_id>
    <nct_id>NCT00025636</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EBMT Solid Tumors Working Party</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Peripheral stem cell transplant may allow the doctors to give
      higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which
      combination chemotherapy regimen given before peripheral stem cell transplant is more
      effective in treating relapsed Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is comparing different regimens of combination
      chemotherapy followed by peripheral stem cell transplant to see how well they work in
      treating patients with relapsed Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of induction chemotherapy followed by combination chemotherapy and
           autologous peripheral blood stem cell transplantation with or without high-dose
           sequential chemotherapy in terms of freedom from treatment failure in patients with
           relapsed Hodgkin's lymphoma.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the complete remission/unconfirmed complete remission rate at 3 months,
           relapse-free survival, and overall survival of patients treated with these regimens.

        -  Compare the frequency of severe toxic effects and secondary neoplasia in patients
           treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, type of relapse (early first relapse [remission duration 3-12 months]
      vs late first relapse [remission duration more than 12 months] vs second relapse without
      prior high-dose chemotherapy salvage [remission duration after salvage at least 3 months]),
      disease status at relapse (stage I or II vs stage III or IV), age (18 to 49 vs 50 to 60), and
      response after 2 courses of study induction chemotherapy (complete remission vs partial
      remission vs no change).

      All patients receive induction chemotherapy comprising dexamethasone IV over 30 minutes on
      days 1-4 and 15-18, cisplatin IV continuously over 24 hours on days 1 and 15, cytarabine IV
      over 3 hours every 12 hours on days 2 and 16, and filgrastim (G-CSF) subcutaneously (SC) once
      daily on days 5-12 and days 19-26. Patients with complete remission (CR), unconfirmed CR,
      partial remission, or no change are randomized to one of two treatment arms.

        -  Arm I: Patients receive BEAM chemotherapy comprising carmustine IV over 30 minutes and
           melphalan IV over 30 minutes on day 37 and etoposide IV over 30 minutes every 12 hours
           and cytarabine IV over 30 minutes every 12 hours on days 37-40. Patients also receive
           G-CSF SC twice daily beginning on day 41 and continuing until blood counts recover.
           Autologous peripheral blood stem cells (PBSCs) are reinfused on day 42.

        -  Arm II: Patients receive high-dose cyclophosphamide IV over 8 hours on day 37, high-dose
           methotrexate IV over 6 hours and high-dose vincristine IV on day 51, and high-dose
           etoposide IV over 8 hours on days 58-61. Patients then receive BEAM chemotherapy
           comprising carmustine IV over 30 minutes and melphalan IV over 30 minutes on day 80 and
           etoposide IV over 30 minutes every 12 hours and cytarabine IV over 30 minutes every 12
           hours on days 80-83. Patients also receive G-CSF SC once on days 38 and 62 and twice
           daily beginning on day 84 and continuing until blood counts recover. Autologous PBSCs
           are reinfused on day 85.

      Patients with residual lymphoma at 100 days after completion of BEAM chemotherapy may receive
      radiotherapy.

      Patients are followed at 100 days after PBSC transplantation, every 3 months for 2 years,
      every 6 months for 2 years, and then annually thereafter.

      PROJECTED ACCRUAL: A minimum of 220 patients (110 per treatment arm) will be accrued for this
      study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy at 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity at 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission at 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival at 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 3 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed Hodgkin's lymphoma

          -  Early or late first relapse

               -  Complete or partial remission for at least 3 months after completion of prior
                  COPP/ABVD, COPP/ABV/IMEP, MOPP/ABV, ABVD, BEACOPP, or other polychemotherapy
                  regimen with or without radiotherapy

               -  No prior salvage therapy OR

          -  Second relapse

               -  Any prior salvage therapy

               -  No prior high-dose chemotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 60

        Performance status:

          -  Karnofsky 70-100% OR

          -  ECOG 0-2

        Life expectancy:

          -  More than 3 months with treatment

        Hematopoietic:

          -  Absolute neutrophil count at least 2,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No uncontrolled hypertension (diastolic blood pressure greater than 115 mm Hg)

          -  No unstable angina

          -  No New York Heart Association class III or IV heart disease (congestive heart failure)

          -  No myocardial infarction within the past 6 months

          -  No uncontrolled atrial or ventricular cardiac arrhythmias

        Pulmonary:

          -  No chronic pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No active infection

          -  No poorly controlled diabetes

          -  No cerebral disorder

          -  No other concurrent malignancy except adequately treated basal cell skin cancer or
             cervical intraepithelial neoplasia

          -  No significant non-malignant disease

          -  No psychiatric, addictive, or other disorder that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  Not specified

        Other:

          -  At least 6 months since prior coronary angioplasty

          -  No other concurrent investigational drugs

          -  No concurrent non-steroidal anti-inflammatory drugs, salicylate, sulfonamide,
             trimethoprim, allopurinol, aminoglycoside, amoxicillin, or probenecid during high-dose
             methotrexate administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert, MD</last_name>
    <affiliation>Medizinische Universitaetsklinik I at the University of Cologne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. W. Baars, MD, PhD</last_name>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Schmitz, MD, PhD</last_name>
    <affiliation>Asklepios Klinik St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint Lucas</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rebro</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Poliklinik</name>
      <address>
        <city>Bonn</city>
        <zip>D-53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <zip>D-06822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Essen Werden</name>
      <address>
        <city>Essen</city>
        <zip>D-45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universitaet</name>
      <address>
        <city>Halle</city>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>DOH-59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Siloah - Medizinische Klinik II</name>
      <address>
        <city>Hannover</city>
        <zip>D-30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik und Poliklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus</name>
      <address>
        <city>Hildeshem</city>
        <zip>D-31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Schiller Universitaet Jena</name>
      <address>
        <city>Jena</city>
        <zip>D-07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Muenchen Schwabing</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum - Veldhoven</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra (HUC)</name>
      <address>
        <city>Coimbra</city>
        <zip>P-3001-301</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

